Anchor Capital Advisors LLC Lowers Stock Position in Boston Scientific Co. (NYSE:BSX)

Anchor Capital Advisors LLC lessened its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,111,185 shares of the medical equipment provider's stock after selling 56,534 shares during the period. Boston Scientific makes up 1.7% of Anchor Capital Advisors LLC's portfolio, making the stock its 14th biggest position. Anchor Capital Advisors LLC owned about 0.08% of Boston Scientific worth $64,238,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. Victory Capital Management Inc. boosted its stake in Boston Scientific by 5.6% in the 3rd quarter. Victory Capital Management Inc. now owns 518,047 shares of the medical equipment provider's stock valued at $27,353,000 after buying an additional 27,620 shares in the last quarter. Louisiana State Employees Retirement System bought a new stake in shares of Boston Scientific in the 4th quarter worth about $5,116,000. Glenmede Trust Co. NA increased its position in shares of Boston Scientific by 12.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider's stock worth $551,000 after purchasing an additional 1,123 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Boston Scientific by 2.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,868,991 shares of the medical equipment provider's stock valued at $98,683,000 after purchasing an additional 38,249 shares during the last quarter. Finally, HealthInvest Partners AB acquired a new position in Boston Scientific in the fourth quarter valued at about $3,746,000. Institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Royal Bank of Canada lifted their target price on shares of Boston Scientific from $78.00 to $82.00 and gave the company an "outperform" rating in a research note on Thursday. TD Cowen lifted their price objective on Boston Scientific from $65.00 to $77.00 and gave the company an "outperform" rating in a research report on Thursday, March 7th. Robert W. Baird increased their target price on Boston Scientific from $79.00 to $84.00 and gave the stock an "outperform" rating in a report on Thursday. Oppenheimer lifted their price target on Boston Scientific from $58.00 to $68.00 and gave the company a "market perform" rating in a report on Thursday, February 1st. Finally, Citigroup increased their price objective on shares of Boston Scientific from $79.00 to $85.00 and gave the stock a "buy" rating in a report on Thursday. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $75.09.

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig sold 7,000 shares of the company's stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the sale, the director now owns 41,374 shares in the company, valued at approximately $2,690,551.22. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, EVP John Bradley Sorenson sold 16,351 shares of Boston Scientific stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the transaction, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,509,213.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig sold 7,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now directly owns 41,374 shares of the company's stock, valued at $2,690,551.22. The disclosure for this sale can be found here. Insiders have sold a total of 60,797 shares of company stock valued at $4,138,090 over the last three months. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Trading Down 0.9 %

NYSE BSX traded down $0.69 on Monday, reaching $72.48. The company had a trading volume of 9,463,878 shares, compared to its average volume of 6,623,186. The company has a quick ratio of 0.82, a current ratio of 1.32 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $74.39. The stock has a market cap of $106.34 billion, a price-to-earnings ratio of 60.91, a PEG ratio of 2.52 and a beta of 0.78. The stock's 50 day moving average is $67.96 and its 200-day moving average is $60.80.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating analysts' consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 16.63% and a net margin of 12.06%. The company had revenue of $3.73 billion during the quarter, compared to analysts' expectations of $3.59 billion. During the same period in the prior year, the business posted $0.45 EPS. Equities analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.